Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human ALN-SNCA study in adults with early Parkinson's disease
NL-OMON60055Phase 1Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of ALN-SNCA in Parkinson's disease (PD), sponsored by Regeneron Pharmaceuticals. Started Nov 2025; status: recruiting.
02
Drugs
ALN-SNCA
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON60055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60055.